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mn May 3, 2006, I had the privilege of moderating a
debate between Dr. John W. Brown and Dr. Joseph A.
earani. The debaters were selected on the basis of their
xtensive experience and expertise in the area of right ven-
ricular outflow tract (RVOT) reconstruction. Twenty years
go, reports on the use of mechanical valves (MV) in the
VOT concluded that the short- and long-term outcomes
ere inferior to those reported for bioprostheses (BP) and
omografts (HG). In this debate, each participant carefully
eviewed the 40 year history of RVOT reconstruction at
heir institution and then they addressed the potential role of
n MV in the RVOT.
Dr. Brown reported that only three patients have received
mechanical valve in the RVOT at Indiana University. All
hree of these patients had another mechanical valve in place.
r. Brown quoted the Mayo Clinic data to indicate that late
eoperation for re-replacement of an adult-sized porcine bio-
rosthesis in the RVOT was rarely necessary. He stated that,
n his extensive personal experience, 75% of adult-sized bio-
rosthesis in the RVOT were still in place at 25 years. This
tatement was supported by an actuarial curve which is not
eproduced in his manuscript. Dr. Brown also discussed mo-
ocusp RVOT valves and bovine jugular valved conduits in
he RVOT. Dr. Brown summarized seven publications de-
cribing the use of a mechanical valve in the RVOT. Although
ecent reports suggest that a mechanical valve might be ap-
ropriate in the RVOT, Dr. Brown concluded that implanting
n isolated mechanical valve in the RVOT would be very
arely indicated. In his opinion, there is relatively low risk in
e-replacing a bioprosthesis. He suggested the routine use of
Gore-Tex pericardial substitute to facilitate reentry sternot-
my and stressed the need to oversize a bioprosthesis in the
VOT whenever possible.
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doi:10.1053/j.optechstcvs.2006.07.001In his presentation, Dr. Dearani referred to a patient pop-
lation consisting of 2265 patients undergoing RVOT recon-
truction at the Mayo Clinic since 1965: 1540 patients re-
eived a bioprosthesis; 697 patients received an HG; and 28
atients received a mechanical valve (1.2%). Dr. Dearani
onceded that the early reports regarding a mechanical valve
n the RVOTwere not favorable. However, he was inclined to
ive some credibility to recent reports suggesting that there
ay be a role for amechanical valve in the RVOT. Dr. Dearani
resented his technique for implantation of a mechanical
alve in the RVOT. Dr. Dearani also discussed the issue of
roper anticoagulation for a person with a mechanical valve
n the RVOT. Little hard data exist regarding the optimal
nticoagulation regimen for patients with a mechanical valve
n the RVOT. It has been suggested that a mechanical valve in
he RVOT is probably slightly more thrombogenic than the
ame valve in the aortic position. Accordingly, Dr. Dearani
ecommends a target INR of 3.0 (range 2.5 to 3.5). In addi-
ion to warfarin, theMayo Clinic group prescribes one 81-mg
spirin tablet per day. Dr. Dearani emphasized that there is an
ncreased risk, documented in the literature, for patients un-
ergoing their fourth sternotomy, ie, multiple reoperations
ay not be as benign as Dr. Brown suggested. His presenta-
ion was more encouraging on the subject of the mechanical
alve in the RVOT since he thinks that safer anticoagulation
edications may become available in the future. If a lower
isk anticoagulation regimen became a reality, the durability
f a mechanical valve could become an important consider-
tion when deciding on the appropriate RVOT prosthesis for
n individual patient.
In the rebuttal section of the debate, Dr. Brown reiterated
is concerns about committing patients to a lifetime of anti-
oagulation. Dr. Brown also mentioned the possible effect on
djacent structures when the rigid mechanical valve is in-
erted. He stressed that a mechanical valve would be inap-
ropriate for a young female contemplating pregnancy. He
oncluded that the role for a mechanical valve in the RVOT
as probably limited to those patients that already had a
echanical valve in another position.
In rebuttal, Dr. Dearani reviewed his presentation and em-hasized that many patients require associated procedures at
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Biological versus mechanical valve replacement 217he time of RVOT surgery. While both debaters concluded
hat the role of a mechanical valve in the RVOT was limited
tilizing present prostheses and anticoagulation regimens,
r. Dearani seemed more willing to consider the use of an
solated mechanical valve in the RVOT.
I found the debate quite enjoyable and informative. Inter-
stingly, neither debater suggested any role for HG valves in
dult patients undergoing late re-reconstruction of the
VOT. I suspect that this shift away from HG valves in older
atients reflects the need for a valve that will be competent for
any years before failing. I am personally a bit skeptical
egarding the long-term (15 to 20 years) function of the
urrent generation of bioprosthesis (porcine stented/non-
tented, and bovine pericardial) in younger patients. I antic-
pate that most young adults with satisfactory cardiac func-
ion following repair of complex congenital heart defects will
utlive their adult-sized prostheses. Dr. Brown’s actuarial
urve predicted that some patients will have a porcine bio-
rosthesis that “lasts” 25 years. The statistical veracity of this qtatement was hard to assess since there were no numbers or
onfidence limits on his graph. The duration of time that a
ioprosthesis is deemed functional is not only a reflection of its
urability, it is also a reflection of the indications for re-replace-
ent. The current indications for re-replacement of a biopros-
hesis in the RVOT remain a bit subjective. In asymptomatic
atients that are free of objective signs of right ventricular dys-
unction or arrhythmias, a moderate degree of bioprosthetic
tenosis/insufficiency can be well tolerated for years.
In summary, I believe that there will be an increasing role
or mechanical valves in the RVOT and I look forward to
dvances in the field of therapeutic anticoagulation, which
ill permit relatively risk-free long-term anticoagulation. At
he conclusion of the debate, I posed a question to the debat-
rs: Should an adult patient requiring reoperation on the
VOT be offered the option of a mechanical valve as part of
nformed consent? The debate concluded without a real an-
wer to that question. At my institution, the answer to this
uestion is yes.
